AbbVievs.Pfizer
ABBV vs PFE · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 3.2× larger than Pfizer by market cap; Pfizer trades at the lower P/E (18.5 vs 120.6); year to date, AbbVie leads (+8.6% vs −2.9%).
Side by side
| ABBV | PFE | |
|---|---|---|
| Market cap | $438B | $138B |
| Price | $248.08 | $24.17 |
| Today | −0.7% | −0.3% |
| Return YTD | +8.6% | −2.9% |
| Return 1Y | +27.2% | −6.2% |
| P/E | 120.6 | 18.5 |
| P/S | 7.0 | 2.2 |
| P/B | 308.7 | 1.5 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AbbVieABBV
Large biopharma with immunology (Skyrizi, Rinvoq), oncology and neuroscience.
Full ABBV profile →PfizerPFE
Large American pharmaceutical group with a broad portfolio in vaccines, oncology and internal medicine.
Full PFE profile →More comparisons in Big pharma
See where ABBV and PFE sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →